Navigation Links
Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
Date:2/8/2013

roteins from the manufacturing medium and storage solution.

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Through our deep understanding of patients' needs, we develop and provide healthcare in the areas of:

  • Behavioral Health and Gastro Intestinal conditions
  • Rare Diseases
  • Regenerative Medicine

as well as other symptomatic conditions treated by specialist physicians.

We aspire to imagine and lead the future of healthcare, creating value for patients, physicians, policymakers, payors and our shareholders.

http://www.shire.com

FORWARD - LOOKING STATEMENTS - "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included in this announcement that are not historical facts are forward-looking statements. Forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, that:

  • Shire's products may not be a commercial success;
  • revenues from ADDERALL XR are subject to generic erosion;
  • the failure to obtain and maintain reimbursement, or an adequate level of reimbursement, by third-party payors in a timely manner for Shire's products may impact future revenues and earnings;
  • Shire relies on a single source for manufacture of certain of its products and a disruption to the supply chain for those products may result in Shire being unable to continue marketing or developing a product or may result in Shire being unable to do so on a commercially viable basis;
  • Shire uses third party manufacturers to manufacture many of its products and is reliant upon thir
    '/>"/>

SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
2. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
3. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
4. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
5. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
6. Shire Changes its NASDAQ Ticker Symbol to SHPG
7. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
8. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
9. Shire Reaches Agreement in Principle With U.S. Government
10. Palm Beach Residents to Learn How the Future of Regenerative Medicine Will Combat Aging
11. ODT Forum Presents Regenerative Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 Custom Learning Designs, Inc.(CLD) ... solution using Tin Can API combined with its ... is a leading developer of training content and ... worldwide. , Tin Can API is a ... and trainers more accurately measure the Return on ...
(Date:5/21/2013)... , May 21, 2013 ... Dialysis and Transplant Association) is the biggest congress in ... replacement therapy. Nearly 10,000 participants are in ... the latest research findings. New pioneering studies have been ... "SOLUBLE FERRIC PYROPHOSPHATE (SFP) ADMINISTERED VIA HEMODIALYSATE REDUCES ESA ...
(Date:5/21/2013)... According to a new market ... "Biochip Products and Services Market (Microarrays, Reagents, Drug Discovery, ... Share, Growth, Trends and Forecast, 2012 - 2018," the market was valued ... to grow at a CAGR of 10.1% from 2012 ... 4.7 billion in 2018. Browse the full ...
(Date:5/21/2013)... 2013  MacroGenics, Inc. today announced that an ... an Fc-modified chimeric monoclonal antibody (MAb), in patients ... will be presented at the 2013 Annual Meeting ... the Developmental Therapeutics - Immunotherapy Oral Abstract Session ... PM.  The presentation will describe the results of ...
Breaking Biology Technology:CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
... Ortho Biotech is pleased,with recommendations of ... Renal Drugs Advisory Committee (CRDAC) and Drug ... from the,Committees, evaluation of the use of ... failure (CRF). "Ortho Biotech supports the ...
... 11 ACCESS PHARMACEUTICALS, INC.,(OTC Bulletin Board: ... Marcial of BusinessWeek, highlighted Access Pharmaceuticals in ... The article is also available,on http://www.BusinessWeek.com ... The article focused upon the major ...
... Additional Phase 3 Trials on Track for Initiation Later ... for Today at 8:30 a.m. Eastern Time -, ... ARNA ) announced today that an independent Echocardiographic,Data Safety ... to stop,the ongoing pivotal Phase 3 trial, BLOOM (Behavioral ...
Cached Biology Technology:Ortho Biotech Supports FDA Advisory Committees' Recommendations on Use of ESAs in Chronic Renal Failure Patients 2Ortho Biotech Supports FDA Advisory Committees' Recommendations on Use of ESAs in Chronic Renal Failure Patients 3Ortho Biotech Supports FDA Advisory Committees' Recommendations on Use of ESAs in Chronic Renal Failure Patients 4Ortho Biotech Supports FDA Advisory Committees' Recommendations on Use of ESAs in Chronic Renal Failure Patients 5Access Highlighted in Recent BusinessWeek Article 2Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review 2Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review 3Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review 4Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review 5Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review 6
(Date:5/22/2013)... May 22, 2013. Plastic additives known as phthalates ... everywhere: They turn up in flooring, plastic cups, ... the Centers for Disease Control and Preventionthe bodies ... have come under increasing scrutiny. A growing collection ... can leech from packaging and mix with food) ...
(Date:5/21/2013)... "place" is increasingly being considered in the management ... new resource that can help them recognize and ... places in their lives. , Place-Based Conservation: ... co-edited by the Pacific Northwest Research Station,s Linda ... to conservation. The book is published by Springer ...
(Date:5/21/2013)... at USC have found that a class of pharmaceuticals ... , The drugs, known as "TSPO ligands," are ... looked at the effects of TSPO ligand in young ... and in aged mice when pathology was quite severe," ... School of Gerontology. "TSPO ligand reduced measures of pathology ...
Breaking Biology News(10 mins):Study links chemicals widely found in plastics and processed food to elevated blood pressure in children and teens 2Drugs found to both prevent and treat Alzheimer's disease in mice 2
... Institute is home to a rich trove of biological ... genetic Library of Congressholds over 147,000 plasmids, (circular DNA ... as well as full genome collections from numerous organisms ... A new $6.5 million grant from the National ...
... its initial appearance in New York in 1999, West Nile ... years and is now well established throughout North and South ... birds that are important hosts for the virus are abundant ... As a result, transmission of West Nile virus is highest ...
... (NSF) has awarded $3 million to Clemson University to ... sensors to monitor water quality along the entire length ... represents a ,big idea, worthy of Thomas Green Clemson, ... scientific research and education," said Clemson President James F. ...
Cached Biology News:Clearing house for DNA gets a boost 2Clearing house for DNA gets a boost 3West Nile virus transmission linked with land-use patterns and 'super-spreaders' 2West Nile virus transmission linked with land-use patterns and 'super-spreaders' 3Clemson's Intelligent River technology to provide real-time monitoring of river 2Clemson's Intelligent River technology to provide real-time monitoring of river 3Clemson's Intelligent River technology to provide real-time monitoring of river 4
GlutaMAX-I Supplement...
... Dissociation Buffers are membrane-filtered isotonic and ... agents and cell-conditioning agents in either ... solution or Ca2+- and Mg2+-free ... mammalian cells from support substrates and ...
Goat polyclonal to PINX1 ( Abpromise for all tested applications). entrezGeneID: 54984 SwissProtID: Q548A5...
...
Biology Products: